Corcept Q2 revenue up 32% to $256M; raises FY2026 guidance to $1.1-1.2B

CORCEPT THERAPEUTICS INC

Revenue $256.1M (+32% YoY); net income $43.0M ($0.36 diluted EPS) vs $35.1M ($0.29) in Q2 2025.
Lifyorli (relacorilant) generated $47.6M in first quarter of availability; over 1,300 patients started treatment.
FY2026 revenue guidance increased to $1.1-1.2 billion.
NDA for relacorilant in Cushing's syndrome resubmitted; PDUFA date December 17, 2026.
Cash and investments $544.6M at June 30, 2026, up from $515.4M at March 31, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.